Clinical trials: Dementia of Alzheimer Type
Alzheimer's Type Dementia, Cognitive Decline
The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients
This research study is developed on an experimental design with randomized controlled intervention were participated 135 subjects with AD including 45 of the control group.
- Conditions
- Alzheimer's Type Dementia, Cognitive Decline, Postural; Strain
- Trial name
- GPR (NCT03732053)
- Testing
- GPR Intervention Research group
- Volunteers
- 135 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD
Alzheimer Disease
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
- Trial name
- NCT00041678
- Testing
- aripiprazole
- Where
- 6 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease, Lewy Body Disease
LESCOD: "Lewy Body Screening in Cognitive Disorders"
Dementia with Lewy body (DLB) is the second most common neurodegenerative dementia in autopsy series. However, DLB represents a small proportion of the clinical diagnoses in epidemiology registries.
- Trial name
- LESCOD (NCT02263287)
- Testing
- LeSCoD scale
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Nantes University Hospital
Dementia, Dementia Alzheimers
Persons With Dementia and Their Extended Family Caregivers
Immediate family members shoulder the majority of care responsibilities for persons living with dementia. However, due to various societal changes, elder care responsibilities have expanded to extended family members, including…
- Conditions
- Dementia, Dementia Alzheimers, Neuro-Degenerative Disease, Dementia of Alzheimer Type
- Trial name
- CareEx (NCT04863859)
- Where
- United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Karen Roberto
Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with…
- Conditions
- Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
- Trial name
- NCT00208819
- Testing
- risperidone, quetiapine, olanzapine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Emory University
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Alzheimer Disease, Dementia
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo.
- Trial name
- NCT00322036
- Testing
- MPC-7869
- Where
- 92 sites in United States, Belgium and 10 more
- Volunteers
- 800 people
- Sponsor
- Myrexis Inc.
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Dementia, Dementia Alzheimers
Implementation of a Diagnostic Decision-aid for People With Memory Complaints and Their General Practitioners
In a mixed-methods design the investigators will study decision making processes and experiences regarding a diagnostic trajectory before and after the introduction of a patient decision aid for people with memory complaints…
- Conditions
- Dementia, Dementia Alzheimers, Dementia, Mild
- Trial name
- S-DeciDeD (NCT04531956)
- Testing
- Diagnostic decision aid s-decided
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Maastricht University
Alzheimer Disease
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild…
- Trial name
- NCT00153010
- Testing
- NS 2330 (Tesofensine)
- Where
- 87 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- Boehringer Ingelheim
Hearing Loss, Sensorineural, Dementia of Alzheimer Type
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
This current translational project, funded by NIH, aims to better understand the impact of various signal modification strategies for older adults with Alzheimer's dementia and its potential precursor, known as amnestic mild…
- Conditions
- Hearing Loss, Sensorineural, Dementia of Alzheimer Type, Amnestic Mild Cognitive Impairment
- Trial name
- NCT04240561
- Testing
- High level of signal manipulation, Low level of signal manipulation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Alzheimer's Disease, Dementia
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
- Trial name
- NCT00338117
- Testing
- Galantamine hydrobromide
- Volunteers
- 554 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Behavioral and Psychological Symptoms of Dementia, Dementia
Validation and Reliability of the Turkish Version of the Montreal Cognitive Assessment-Basic (MoCA-B) in Individuals With Low Educational Level
This study aimed to evaluate the validity, reliability, and diagnostic accuracy of the Turkish version of MoCA-B in distinguishing healthy controls, mild cognitive impairment (MCI), and dementia patients within a low-education…
- Conditions
- Behavioral and Psychological Symptoms of Dementia, Dementia, Dementia (Diagnosis), Dementia Alzheimer Type
- Trial name
- MoCA-B Turkish (NCT07630688)
- Where
- Turkey (Türkiye)
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Alzheimer Disease, Dementia of Alzheimer Type
DMB-I in the Treatment of Alzheimer Type Dementia
The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
- Trial name
- NCT06292351
- Testing
- DMB-I (Dimebon)
- Where
- 7 sites in Russia
- Volunteers
- 133 people
- Sponsor
- Bigespas LTD
Alzheimer Disease
A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease
This clinical trial is designed to evaluate the initial safety and efficacy of opening the blood brain barrier (BBB) in patients with Alzheimer's disease using the ExAblate 4000 Type 2.1, a MR guided high-intensity focused…
- Trial name
- NCT06474013
- Testing
- ExAblate 4000 Type 2.1
- Volunteers
- 15 people
- Sponsor
- Korea University Anam Hospital
Amyloid, Amyloidosis
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
The investigators will prospectively evaluate for the presence of amyloid deposits in ligamentum flavum (yellow ligament) tissue samples obtained from patients undergoing spinal stenosis surgery.
- Conditions
- Amyloid, Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis
- Trial name
- ALF (NCT03923920)
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- NCT06736509
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 139 people
- Sponsor
- Axsome Therapeutics, Inc.
Dementia of Alzheimer Type
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).
- Trial name
- NCT04749563
- Testing
- IGC AD1
- Where
- Puerto Rico
- Volunteers
- 12 people
- Sponsor
- IGC Pharma, LLC